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have demonstrated a differential effects of RTX in
depleting B-cells and blocking plasma cell gener-
ation at the synovial and at the bone marrow level
(7-9). This differential effect may explain why
among patients who respond to RTX, some relapse
while others show a very prolonged response, in-
dependently from the reappearance of B-cells in the
peripheral blood (6). However, the efficacy of RTX
may also depend on the individual genetic predis-
position. At this regard, very few data were pro-
duced by now.
IL-6 is a key cytokine in RA pathogenesis, driving
both the systemic inflammation and the synovial
joint destruction, as proved by the important re-
sults of the anti-IL-6 therapy in RA patients (10,
11). Furthermore, IL-6 has a fundamental role in
INTRODUCTION
Several studies demonstrated the efficacy of theB-cell depletion therapy with rituximab (RTX)
in RA patients, including those unresponsive to an-
ti-TNF therapy, underlying the important role of B
cells in this disease (1-5). Several recent papers
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RIASSUNTO
Visto l’elevato costo della terapia con rituximab (RTX), l’identificazione di marcatori biologici predittivi di risposta
rappresenta un importante obiettivo. In questo studio è stato analizzato il polimorfismo -174G>C del promotore
dell’IL-6, citochina chiave nella proliferazione B cellulare, quale potenziale marcatore di efficacia del RTX in una co-
orte “real-life” retrospettiva di 142 pazienti con artrite reumatoide trattati con RTX presso 7 differenti Centri Reu-
matologici Italiani. La risposta clinica è stata valutata alla fine del sesto mese dopo la prima infusione di RTX utiliz-
zando sia i criteri EULAR (DAS28) chi i criteri ACR. Lo studio ha evidenziato una significativa associazione tra il ge-
notipo -174CC e la non risposta al RTX al mese +6 sia secondo i criteri EULAR, (OR 3,196, 95% CI=1,204-8,485;
p=0,0234), che secondo i criteri ACR. Il polimorfismo -174G>C dell’IL-6, coinvolto nei meccanismi di regolazione
dell’espressione della citochina, appare pertanto un nuovo possibile marcatore in grado di identificare i pazienti con
AR ad elevato rischio di non risposta al RTX.
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B cell survival and proliferation (12), and then its
expression may be involved in RTX efficacy.
IL-6 exerts its biological activities through inter-
action with its specific receptor called gp80 or IL-
6R alpha on the surface of target cells. The IL-
6/IL-6R alpha complex recruits two signal-trans-
ducing beta gp130 subunits, leading to the forma-
tion of the high-affinity IL-6 receptor complex and
finally to signal transduction (13, 14). The IL6R al-
pha and beta exist also as soluble forms are gener-
ated by either proteolytic cleavage of their mem-
brane moiety or by alternative splicing. The asso-
ciation of IL-6 with the soluble form of IL-6R al-
pha is capable of eliciting a biological response in
cells that express only the membrane gp130. This
type of activation, called “trans-signalling”, ren-
ders virtually all cells capable of responding to IL-
6/sIL-6R alpha complexes (15, 16). Different IL-6
or soluble IL-6R alpha (sIL-6Ra) levels have been
described due to specific polymorphisms in IL-6
and IL-6R genes (17-22). We here investigated a
possible association between RA response to RTX
and the -174G>C IL-6, previously associated with
different IL-6 serum levels in RA patients (17).
PATIENTS AND METHODS
Patients
The study was conducted in a real-life retrospec-
tive cohort of 142 unselected patients (120 females
and 22 males; mean age 60.2±12.9 years) with RA
diagnosed according to the ACR classification cri-
teria (23). The disease duration was 13.9±10 years.
All patients gave their informed consent to the
study according to the Declaration of Helsinki and
the investigation was approved by the local Study
Review Board. Patients were referred to seven dif-
ferent rheumatologic Centres in the North of Italy.
One hundred and thirteen (79.6%) patients were
rheumatoid factor (RF)-positive and 112 (78.9%)
were anti-CCP antibodies positive. All patients
were treated with RTX intravenous infusions (500
mg at weeks 0, 1, 2, 3 or 1,000 mg at weeks 0,2)
in monotherapy (9 cases) or in combination with
methotrexate (MTX) (124 cases) or other disease
modifying anti-rheumatic drugs (DMARDs:
leflunomide, cyclosporin A or hydroxychloro-
quine; 9 cases). One hundred and four (73.2%) pa-
tients had been previously treated with one or more
anti-TNF agents. Thirty-eight patients did not ex-
perience any biologic therapy before RTX, but
were unresponsive to MTX alone or in combina-
tion with other DMARDs for at least 6 months.
The efficacy of RTX was evaluated at the end of
the sixth month after the first RTX infusion, using
both the European League Against Rheumatisms
(EULAR) response criteria, (mean baseline
DAS28 6.17±1.11, range 3.00-8.52) and the Amer-
ican College of Rheumatology (ACR) response
criteria (considering responder patients when
ACR≥50).
Genetic analyses
DNA was extracted by EDTA-treated peripheral
blood using an automated methodology (Maxwell
16, Promega, Madison, WI, USA) and dedicated
kits (Maxwell 16 Blood DNA purification kit). The
analysis of the -174G>C IL-6 promoter polymor-
phism was made following previously reported
methods (19). Briefly, the followings forward and
reverse primers were used: 5’-TGACTTCAGCTT-
TACTCTTGT-3’ and 5’-CTGATTGGAAACCT-
TATTAAG-3’; in a PCR amplification protocol
comprising 39 cycles composed by the following
3 steps: 1 minute at 95°C, 1 minute at 55°C, 1
minute at 72°C. PCR products were finally digest-
ed with NlaIII (New England Biolabs) and run on-
to a 3.5% ethidium bromide-stained agarose gel.
Statistical analyses
Chi-square tests for categorical variables and non-
parametric t tests for quantitative variables were
used using the GraphPad and InStat softwares. Re-
sults were considered statistically significant for
p£0.05.
RESULTS
Response to RTX at month +6 in the population
under study
As illustrated in figure 1, a great concordance was
found between the EULAR and ACR response cri-
teria. By EULAR criteria 30/142 (21.1%) patients
were good responders, 80/142 (56.3%) moderate re-
sponders and 32/142 (22.5%) non responders (NR).
By the ACR response criteria, 91/142 (64.1%) dis-
closed a major response (26 ACR70/90 patients plus
65 ACR50 patients), while 51/142 (35.9%) were
considered non responders (comprising 26 ACR20
patients and 25 null responder patients).
Prevalence of the -174G>C IL-6 genotypes 
in the population under study
The prevalence of the IL-6 -174G>C genotypes in
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was present in 94/113 (83.2%) of RF-positive RA
patients versus 16/29 (55.2%) of the RF-negative
RA patients (OR=4.020, 95% CI=1.663-9.717;
p=0.0025). The same results were obtained when
evaluating the response to RTX by ACR criteria
(data not shown).
DISCUSSION
The list of the biologic agents available for RA
treatment is continuing growing, but the cost of
these drugs are still elevated, thus the identification
of biomarkers able to predict response to each spe-
the present RA series (GG: 42.3%, GC: 42.9%,
and CC: 14.8%) was comparable to the prevalence
already published in other Caucasian RA series
(17, 21, 22). No significant difference in genotype
distribution was found with respect to patient age,
sex, disease duration, baseline DAS28, C-reactive
protein (CRP), health assessment questionnaire
(HAQ), RF and anti-CCP antibodies status, and the
number of previously failed anti-TNF agents.
No response to RTX at month +6 is associated
with the IL-6 -174 CC homozygosis
As illustrated in figure 2, GG and GC patients dis-
closed the same IL-6 genotype distribution ac-
cording to the degree of response to RTX. Thus
they were pooled together and compared to the CC
patients: no response to RTX at month +6 by EU-
LAR criteria resulted more prevalent in the IL-6 -
174 CC RA patients (9/21, 42.8%), than in the
GC/GG patients (23/121, 19%) (OR 3.196, 95%
CI=1.204-8.485; p=0.0234). Moreover, a EULAR
good response was present only in 1/21 (4.8%) of
the CC patients versus 29/121, 23.9% of the
GG/GC patients (OR 0.159; 95% CI=0.0204-
1.234; p=0.0471). Similar results were found when
considering the ACR response criteria, since a poor
response (£ACR50) to RTX was present in 12/21
(57.1%) of CC cases versus 39/121 (32.2%) of
GG/GC cases (OR=2.803, 95% CI=1.090-7.212;
p=0.0465). Of note, the ACR70/90 response was
present in 1/21 (4.8%) of CC cases versus 25/121
(20.7%) of GG/GC cases (OR 0.192; p=ns).
As previously demonstrated (24), a significant as-
sociation between positive RF and response to RTX
was also found in the present RA series: a positive
response to RTX by EULAR criteria at month +6
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Figure 1 - Concordance between EU-
LAR (X-axis) and ACR (Y-axis) criteria
for the evaluation of response to RTX
in the studied population.
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Figure 2 - The relationship between response to RTX at month +6 and
the IL-6 -174G>C polymorphism. The prevalence of the lack of re-
sponse to RTX by EULAR criteria was significantly higher in the IL-6
-174 CC RA patients (9/21, 42.8%), compared to the GC/GG patients
(23/121, 19%), *(OR 3.196, 95% CI=1.204-8.485; p=0.0234).
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cific therapeutic agent is of high priority and rep-
resent also an intriguing challenge for the scientif-
ic community. 
RTX has proved of great efficacy in RA but, as in
the case of other biologic agents, response may
vary between patients, based also on genetic back-
ground. High serum levels of IL-6 are directly cor-
related with disease activity, RF production, leuko-
cyte infiltration, the severity of joint damage and
the systemic manifestations of RA (12, 25) and IL-
6 directly favours B cell survival and proliferation,
being the most abundant cytokine in the rheuma-
toid synovium. Recently a significant decrease of
IL-6 levels were described in the follow-up of RA
patients who respond to RTX (26), but no baseline
biological markers were identified to date. In the
present study we have shown a significant correla-
tion between the -174G>C IL-6 promoter poly-
morphism, linked to IL-6 expression level, and re-
sponse to RTX in RA patients, with comparable re-
sults when evaluating the response either by the
EULAR and by the ACR criteria.
In accordance with previous studies (24, 27), pos-
itive RF again appeared as a strong positive pre-
dictive marker of response to RTX, and this result
reinforce those found about the genetic association
here observed.
Therefore, the analysis of the -174G>C IL-6 pro-
moter polymorphism may be relevant in the eval-
uation of the RA patient for the choice of RTX
therapy.
The main goal of RA therapy is to achieve a good
response, instead of a moderate one. In our series,
patients carrying the IL6 -174CC homozygosis
were very rarely EULAR good responders, if com-
pared to CG/GG - carrying patients (4.8% versus
23.9%), while moderate response was similar in
the 2 groups (52.4% and 57%, respectively). Then,
based on the present results, a good response to
RTX appears very unlikely in patients with RA
showing the IL6 -14 CC genotype and thus, treat-
ments different from RTX might be then consid-
ered in these patients. Anyway, larger replication
studies are needed and still planned by our group
to confirm present results. Of note, the same asso-
ciation between poor response to RTX and the IL-
6 -174CC homozygosis was seen in the present RA
series when subdividing patients as coming from
Eastern or Western areas of north Italy (data not
shown).
Within-population differences in IL-6 concentra-
tion are due both to genetic and environmental in-
fluences. Several papers deal with the genetic reg-
ulation of IL-6 promoter, and IL-6 gene expression
regulation appeared to be affected by complex hap-
lotypes comprising several gene polymorphisms
(28). The -174G>C polymorphism appears as one
major determinant and, recently, a large British
study on 383 RA patients demonstrated higher IL-
6 serum levels in patients with the IL-6 -174CC ho-
mozygosis, who were more prone to develop car-
diovascular complications (17).
According to these findings, the presence of high-
er IL-6 serum levels linked to the CC homozygo-
sis of the -174G>C IL-6 polymorphism associate
with a poor RTX response in RA.
However, when different cytokines were analysed
at baseline and in the follow-up of RA patients
treated with RTX, no predictive baseline profile
was discovered, while a significant decrease of IL-
6 and CRP levels was found in patients showing a
better response (26). The decreased IL-6 expres-
sion following RTX therapy, rather than the base-
line levels, may relate to the degree of response,
and serum IL-6 at baseline did not seem to repre-
sent a useful tool to predict response to RTX (26).
It is widely known that several unpredictable vari-
ables (concomitant drug therapy, concomitant in-
fections, endocrine factors, etc) may affect IL-6
serum levels. Thus, the genetic approach, as we
here investigated, should be a more reliable indi-
cator of IL-6 activity.
Currently, very few data are available about genetic
markers useful, at baseline, to better guide the choice
of RTX therapy in RA. We herein provide prelimi-
nary evidence of a new possible genetic marker, the
CC homozygosis of the -174 IL-6 promoter poly-
morphism, as a predictor of no response to RTX in
RA. This preliminary evidence, if confirmed, may
be relevant to optimize the treatment of RA with
RTX and other biologic agents (6, 10, 29).
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SUMMARY
Objective. Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant is-
sue. The -174G>C interleukin-6 (IL-6) promoter polymorphism was investigated in RA patients treated with rituximab
(RTX), being IL-6 a key cytokine for B cell survival and proliferation, thus possibly implicated in rituximab efficacy.
Methods. The study was conducted in a real-life retrospective cohort of 142 unselected RA patients (120F/22M) treat-
ed with RTX and referred to 7 rheumatologic centres in the north of Italy. One hundred and thirteen (79.6%) patients
were rheumatoid factor (RF)-positive and 112 (78.9%) were anti-CCP antibodies positive. The response to therapy
was evaluated at the end of the sixth month after the first RTX infusion, by using both the EULAR criteria (DAS28)
and the ACR criteria. The IL-6 -174G>C promoter polymorphism was analyzed by RFLP following previously re-
ported methods. 
Results. Lack of response to RTX at month +6 by EULAR criteria was more prevalent in RA patients with the IL-6 -
174 CC genotypes (9/21, 42.8%), than in the GC/GG patients (23/121, 19.0%) (OR 3.196, 95% CI=1.204-8.485;
p=0.0234). Similar results were found when evaluating the response by ACR criteria. No differences were found in
RA duration, baseline DAS28, baseline HAQ, RF status, anti-CCP status according to the different IL-6 -174 geno-
types.
Conclusion. IL-6 promoter genotyping may be useful to better plan treatment with RTX in RA. Larger replication
studies are in course to confirm these preliminary results.
Parole chiave - IL-6, farmacogenetica, rituximab, artrite reumatoide.
Key words - IL-6, pharmacogenetics, rituximab, rheumatoid arthritis.
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